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Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related morbidity and mortality
worldwide. Most patients are diagnosed with advanced disease, limiting their options for treatment.
While current treatments are adequate for lower staged disease, available systemic treatments are
limited, with marginal benefit at best. Chimeric antigen receptor (CAR) T cell therapy, effective in
treating liquid tumors such as B-cell lymphoma, presents a potentially promising treatment option for
advanced HCC. However, new challenges specific to solid tumors, such as tumor immunoanatomy
or the immune cell presence and position anatomically and the tumor microenvironment, need to be
defined and overcome. Immunotherapy currently in use must be re-engineered and re-envisioned to
treat HCC with the hopes of ushering in an answer to advanced stage solid tumor disease processes.
Future therapy options must address the uniqueness of the tumors under the umbrella of HCC.
This review strives to summarize HCC, its staging system, current therapy and immunotherapy
medications currently being utilized or studied in the treatment of HCC with the hopes of highlighting
what is being done and suggesting what needs to be done in the future to champion this therapy as
an effective option.
Keywords: hepatocellular carcinoma; tumor microenvironment; immunoanatomy; immunotherapy;
CAR T cell
1. Introduction
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related mortality
and the leading cause of cancer-related morbidity worldwide [1–3]. Relative to other malignancies,
the incidence of HCC is fifth highest in men and ninth highest in women [4]. Risk factors for these
patients are numerous including—hepatitis B virus (HBV), hepatitis C virus (HCV), non-alcoholic
steatohepatitis (NASH), alcoholic liver disease, tobacco, aflatoxins, vinyl chloride and thorium dioxide,
anabolic steroids, as well as other rare diseases affecting the liver and environmental toxins [5,6].
Advances in preventative measures against conditions leading to HCC, such as the HBV vaccine, have
reduced its incidence, while antiviral therapy in HCV has been able to achieve sustained virologic
responses and disease suppression. Despite these advances, in 2018, global mortality related to HCC
still exceeded 600,000 deaths and is expected to rise to over 1 million by 2030 [7,8].
Unfortunately, early diagnosis is rare due to the vague symptoms associated with liver tumors and
lack of effective identification and screening of non-cirrhotic at-risk populations. These shortcomings
are highlighted by the geographic discrepancy in expert opinion; currently, the United States and
Canada do not recommend any screening owing to a lack of conclusive evidence proving a mortality
benefit in these populations [9,10]. Conversely, the European Association for the Study of the Liver
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(EASL) guidelines support routine 6-month ultrasound surveillance in non-cirrhotic HBV populations
or those with advanced fibrosis, supported by a 2011 meta-analysis of 15,158 patients showing
an association between screening and improved overall survival through early disease detection [11,12].
Similarly in Asia, the Asia Pacific Association for the Study of the Liver (APASL) recommend both
serologic and radiologic surveillance of patients as young as 20 with HBV surface antigen positivity or
those with family history of HCC [13]. Regardless of these heterogeneous screening practices, early
detection and treatment with curative intent is uncommon, reflected in the dismal 18% 5-year survival
and median survival of 6–20 months from time of diagnosis [3,14]. Moreover, HCC tends to present in
its advanced stage necessitating the need for better systemic therapy.
Carcinogenesis in HCC is the result of a variety of ongoing and disparate insults stemming from
heterogeneous disease processes. Regardless of the initial insult, HCC arises in a setting of sustained
inflammation, generation and inadequate clearance of toxic reactive oxygen species and a host of
genomic alterations all causing hepatocellular stress and dysfunction. These ongoing processes disrupt
normal hepatocellular function and lead to several overarching processes, including progressive
genomic instability, cell death and fibrosis of normal hepatocytes leading to cirrhosis and abnormal
hepatocellular regeneration causing dysplastic and neoplastic cellular proliferation each specific to the
causative etiology.
While tumorigenesis in the liver stems from an insult that disrupts normal hepatic and
hepatocellular structure and function, the liver itself is unique to most other solid organs due
to the presence of systematically fixed phagocytotic cells which control bloodstream screening and
clearance. This is known as the reticuloendothelial system (RES) or, more recently, the mononuclear
phagocyte system (MPS) [15]. These terms are, somewhat incorrectly, used interchangeably but the
latter, more modern term, refers to a phagocytic system which is fixed and abundant mainly in the
liver, spleen and lymph nodes [15]. This unique immune-environment in the liver, which we refer to
as the immunoanatomy, plays a vital role in creating conditions utilized by HCC tumor cells.
Most current standard treatments for advanced stage HCC are associated with significant systemic
side effects and a modest at best survival benefit [16]. Advances in immunotherapy, however, have
shown success in treating tumors across multiple organ systems including the lung, kidney, bladder,
lymphoid tissue and skin. As such, it may provide a future therapeutic option for HCC patients.
In this review, we discuss current diagnosis and treatment of HCC, the unique contribution of the
immunoanatomy of the liver in both its natural healthy and HCC disease state and provide an overview
of immunotherapy in HCC from the past and present with the hope of shedding light on where the
field needs to expand in the future.
2. Etiologies Predisposing to HCC
While HCC is defined as a singular entity, the liver pathologies resulting in HCC carcinogenesis
are highly variable depending on the inciting injuries. Each insult utilizes a different process to promote
genomic instability, ongoing inflammation, cellular damage and neoplastic proliferation. Here, we will
provide an overview of each of the main disease processes in the liver that may progress to HCC.
Most cases of HCC are due to viral causes, namely hepatitis B virus (HBV). HBV is a partially
double-stranded DNA virus and can either exist as an acute infection with longstanding immunity or
a chronic infection with the potential for reactivation [17]. HBV causes HCC by directly damaging
hepatocytes leading to deranged regeneration as well as by integrating into the hepatocyte genome
and altering transcription, translation and regulation [18]. The direct insult, acute viral infection of
hepatocytes, activates the highly immunogenic liver immunoanatomy to recruit immune response
cells (i.e., T cells, B cells, macrophages, etc.). The result is inflammation, degeneration and regeneration
of the hepatocytes [18]. In chronic infection, on the other hand, integration of the HBV viral genome
results in immune tolerance of HBV and HBV related molecules in the liver, possibly via inhibition or
decreased expression of a co-inhibitory receptors on T cells that mitigate the CD8 T cell response [19].
Likely this process is carried out via multiple immune- and genome-modulating pathways yet to be
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discovered. Interestingly, the specific immunoanatomy even within HBV can be augmented and/or
modified from other etiologies. For example, aflatoxin exposure has been shown to have a synergistic
effect when combined with HBV, leading to a higher incidence of HCC in patients exposed to both [20].
In the setting of inflammatory regeneration leading to fibrosis and immune tolerance, the liver becomes
vulnerable to HCC neoplastic proliferation.
Alternatively, HCV, which is an RNA virus, cannot integrate into the host hepatocyte genome
and thus requires continued replication [21]. This continuous replication causes chronic inflammation
leading to the degeneration and fibrosis as described above. However, evidence of differing
tumorigenesis and immunoanatomy based on immune cell types present between HBV and HCV
continues to evolve as our understanding of HCC increases [21]. Overall, the chronic, immune-driven
inflammation characteristic of these viral etiologies leads to or creates the milieu that results in the
majority of HCC cases.
Another etiology, non-alcoholic steatohepatitis (NASH), is a growing epidemiologic burden with
the rising prevalence of obesity in the US and worldwide. NASH causes inflammation in hepatocytes
by depositing excess circulating fat globules within the cells. These fatty hepatocytes become distressed
and compete for oxygen leading to inflammation, loss of function and an immune response that
results in subsequent fibrosis [22]. NASH also causes “multiple-parallel” hits whereby fatty deposits
damage and inflame visceral tissues which cause increased metabolic stress in the already weakened
fatty hepatocytes tasked with filtering the molecules of inflammation combined with a globally poor
nutritional state [23]. Specifically, Kupffer cells, which are specialized macrophages located within
the liver sinusoids and part of the normal healthy liver immunoanatomy, are activated, cytokine
production is increased and an environment of fibrosis, regeneration and deranged proliferation is
created [24].
Alcohol is a well-known carcinogen for a variety of cancers and contributes to their development
in a multimodal fashion. Acetaldehyde, the metabolite of ethanol, impairs the cell’s DNA repair
mechanisms through direct cross-linking [25]. Alcohol also leads to the production of reactive oxygen
species, pro-inflammatory cytokines and the downregulation of normal immunosuppression during
metabolism, a process that takes place within hepatocytes [26–28]. These processes combine to damage
and alter hepatocytes, predisposing these cells to mutagenesis and subsequent carcinogenesis.
While each etiology shares the overall theme of insult leading to fibrosis, degeneration, regeneration
and finally mutagenesis ending in HCC tumor cells, the process by which these stages are carried out
is clearly quite heterogeneous. As such, it becomes extremely important to strive to tailor treatment
options based on the specific causative etiology, a task which, as we will see, has yet to be achieved.
3. Current Management of HCC
3.1. BCLC Staging and Treatment Algorithm
Current HCC treatment pathways depend on the stage at which a patient is diagnosed. The most
commonly used staging system in HCC is the Barcelona clinic liver cancer (BCLC) system. The BCLC
system classifies patients into five prognostic groups in order of advancing disease stage—0, A, B, C
and D. The staging system incorporates liver function (Child-Pugh class), tumor burden (number, size,
vascular invasion, metastases) and patient performance status (using the Eastern Cooperative Oncology
Group [ECOG] status) [29]. Patients classified as BCLC stage 0 or A are eligible for curative therapies,
namely surgical resection, liver transplantation and percutaneous radiofrequency ablation. Five-year
survival rates are quoted at greater than 70%. BCLC stage B patients are eligible for locoregional
therapy, such as trans-arterial chemoembolization (TACE) or trans-arterial radioembolization (TARE).
Median survival is quoted at 2 years. BCLC stage C patients have advanced disease defined as
either having portal vein invasion or extrahepatic spread. These patients can be offered systemic
treatment only. BCLC stage D, also called terminal stage, is currently treated symptomatically with
best supportive care [30]. Figure 1 displays the BCLC staging system with a graphic representation
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of the associated anatomy, tumor burden liver and recommended treatment. Noticeably, none of the
available treatment options addresses the etiology of HCC tumor development. In addition, currently
no immunotherapy is considered standard of care for any stage.
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3.2. Surgical Management
Surgical management of HCC is divided into two categories, resection or surgical removal of
part of the liver based on anatomic segments or transplant, the complete removal of the native liver
and replacement from deceased- or live-donor tissue. The decision to resect depends on tumor size,
location and degree of underlying hepatic decompensation. Patients eligible for resection often have
preserved liver function and tumors which are localized anatomically without any vascular invasion,
falling into BCLC categories 0 and A [31–33]. A resection is potentially curative if tumors are solitary
and generally < 5 cm in diameter [31]. Di inished liver function can negate eligibility for resection of
HCC tumors, even those that fit the size, location and i vasion criteria. Though defined by overriding
guidelines, dec sions to r sect can vary between institutions. Recovery from resection is dependent
on th volume of remnant liver a d its underlying functio [32]. Resection for HCC has a role in the
treatmen algorithm but d es not offer a olu i n to patients with high tumor burden, advance HCC,
an /or diminished underlying liver function.
Transplant for is usually reserved for patients in BCLC categories 0 and A who do not
meet the above resection criteria. In the US, the Milan criteria is often used to determine transplant
eligibility for HCC patients. The Milan criteria states that patients who have—(1) a single tumor with
diameter less than 5 cm OR (2) not more than three foci of tumor, each one not exceeding 3 cm AND
(3) no angioinvasion AND (4) no extrahepatic involvement are eligible for liver transplantation [34–36].
In the US, liver transplant is considered the gold standard for treatment of HCC that falls within
the Milan criteria [32]. Additional, more liberal criteria proposed by the University of San Francisco
expanded the Milan criteria to—(1) a single tumor with diameter less than 6.5 cm OR (2) not more than
three foci of tumor, each one not exceeding 4.5 cm OR (3) total tumor diameter not exceeding 8.5 cm
AND (4) no angioinvasion [31,37]. Survival at 1, 3 and 5-years were predictably worse in the UCSF
group compared to Milan, although only late-stage T4 tumors were shown to have inferior outcomes
compared to Milan criteria on multivariable analysis [38]. The use of the Milan criteria, namely in the
US, is likely here to stay and is driven partially by ongoing organ shortages and lack of the robust
living-donor liver programs which exist in other cou tries. This limits the number of patients who
receive liv r t nsplants. In addition, surgical intervention is inva ive and exposes patients to the
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risks of general anesthesia as well as a gamut of surgical complications highlighting the need for less
invasive, more specific treatments.
Radiofrequency ablation (RFA) is being increasingly utilized to treat small, early stage BCLC 0 and
A tumors as well as to treat patients who are at risk to progress while waiting on the transplant list [39].
RFA is the superheating of HCC tumor tissue via radio wave transmission through a probe inserted
through the skin guided by ultrasound or cross-sectional imaging [39]. A recent study, however,
has shown that, in HCC patients who meet the resectability criteria treated with resection versus RFA,
the overall 5-year survival and recurrence-free survival were lower in the RFA group (75 v 54% and
51 v 28%, respectively) [40]. This modality, in its current state, is clearly reserved for patients with
small tumors who cannot tolerate surgical intervention or those on the transplant waiting list who are
at risk of tumor progression but does not offer a solution to patients with advanced HCC, nor is it
superior to current surgical options available.
3.3. Locoregional Therapy
As HCC BCLC stage progresses to B, the patient is often no longer eligible for surgical resection,
transplant or ablation. Instead, reducing tumor burden becomes the goal of treatment. This scenario is
also the case for patients who may be in lower BCLC stages but their diminished overall health renders
them ineligible for safe surgical intervention. Treatments designed for this purpose include the direct
administration of either intra-arterial chemotherapy (trans-arterial chemoembolization (TACE)) or
radiotherapy (trans-arterial radioembolization (TARE)) and are collectively referred to as locoregional
therapy [41,42]. Specifically, TACE involves direct delivery of doxorubicin followed by the blocking
of blood flow via selective hepatic artery branch embolization to ensure chemotherapy dwell time.
Recent advances allow TACE treatment of both early, non-surgical and some late stage patients (BCLC
0, A, B, & some C) with a solitary nodule or up to 3 nodules under 3 cm [41]. One trial, stopped early,
showed that mean survival was significantly longer with TACE compared to symptomatic treatment
alone (28.6 months v 17.9 months) [42].
TARE, on the other hand, utilizes selective intra-arterial injection of radioactive yttrium-90 (Y-90),
iodine-131 (131I) or rhenium-188 (188Re) to cause radiation-induced cell necrosis [43]. Similar to
TACE, TARE is indicated for non-surgical BCLC Stage 0, A, B & some C patients [44]. One study
reported median survival of 16.9 months in BCLC Stage B patients and another retrospective analysis
demonstrated a median survival of 14 months when TARE was used as first-line therapy compared
to 8 months in patients receiving standard therapy [44,45]. Most complications of TARE stem from
radiation damage causing bile duct stricture and cholangitis.
These locoregional methods of treatment for advanced disease, while showing some benefit to
patients, ultimately do not lead to a sustained response. Residual tumor and local recurrence often
necessitate additional TARE or TACE procedures and progression of disease sometimes renders these
locoregional therapies ineffective with no response seen [42]. Also, these procedures are provided
only at selected centers equipped with skilled providers able to perform both the procedure and
post-procedural care. This results in limited availability and a significant healthcare cost. While some
believe there is the potential for locoregional therapy to “downstage” cancers, making the patient
eligible for resection or transplant, this concept has not yet been accepted into standard practice.
3.4. Systemic Therapy
For advanced staged HCC tumors (BCLC B & C), surgical and locoregional therapies are not
recommended. Instead, the disease is so advanced only systemic therapies are applicable in this patient
population. Sorafenib, one of the medications which is FDA approved for advanced HCC, is a systemic
oral therapy which inactivates multiple kinase proteins, including vascular endothelial growth
factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR) and rapidly accelerated
fibrosarcoma (RAF) kinases, halting pathways responsible for angiogenesis and cell growth [46,47].
It is approved for use in the treatment of kidney and thyroid cancer. Sorafenib was tested in late
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stage HCC (BCLC B & C) treatment in the US & European Sorafenib in patients with advanced
hepatocellular carcinoma (SHARP) trial and showed an increased survival versus placebo (10.7 months
v 7.9 months) [16]. This finding was corroborated in a repeat trial done in the Asia-Pacific (6.5 months
v 4.2 months) [48]. Subsequently, other systemic therapies have been marketed as non-inferior to
sorafenib including regorafenib (RESOURCE trial) [49,50], cabozantinib (CELESTIAL trial) [51] and
lenvatinib [49]. Although these medications were the first to offer treatment to late stage HCC patients,
at best they offered a modest 3 month median survival benefit. The shortcomings of sorafenib, beyond
its marginal benefit to the patient, include the frequent intolerance of side effects associated with
treatment. Other systemic medications have more recently been approved for HCC, however further
studies will be required to elucidate their efficacy. No current standard therapeutic modality offers
favorable survival outcomes to patients with advanced stage HCC. However, given the unique nature
of the liver and HCC tumors, immunotherapy may be the answer.
4. Immune Landscape of HCC
4.1. Liver Immunoanatomy
In order to understand how immunotherapy could work in treating HCC, it is first important to
characterize the nuanced complexity behind liver immunogenicity in a healthy state. Liver parenchyma
is characterized by a rich, dense network of hexagonal lobules consisting of a triad of biliary, arterial
and venous structures surrounding a central vein. Within these lobules, 60% of liver parenchyma
is composed of hepatocytes. Amongst the remaining tissue are sinusoids lined with Kupffer cells.
The liver serves numerous critical functions such as protein synthesis, metabolism and detoxification.
The ultimate function of the Kupffer cells is to phagocytose cellular debris from these processes
and remove circulating endotoxins, sometimes activating cytokines and recruiting immune cells in
response [52]. Between the hepatocytes and sinusoids exists the Space of Disse which house the hepatic
stellate cells (HSCs) of Ito. When stressed, HSCs promote fibrosis in response to liver injury or chronic
inflammation leading to cirrhosis [53]. These processes are stressed in the setting of liver injury leading
to rapid recruitment of immune cells, inflammation, fibrosis, and, ultimately, cirrhosis, setting the stage
for mutagenesis and tumorigenesis.
Another critical feature of the liver is its immune regulation and relative immune tolerance [54,55].
Immunomodulation occurs through both innate and adaptive immune responses throughout the organ.
The adaptive immune response is initiated by the priming of naïve T cells in the liver. This process
involves antigen presentation by antigen-presenting cells (APCs) to a matching T cell receptor and
co-stimulatory interaction between B7 ligands on APCs and CD28 receptors on T cells, tailoring
responses to antigens in the liver [56,57]. The innate immune response is mainly regulated by the
fenestrated liver sinusoidal endothelial cells (LSECs) which express both antigen-presenting molecules,
including MHC class I/II and costimulatory CD40, CD80 and CD86 molecules as well as mannose
receptors, promoting antigen uptake [58,59]. In this space, proinflammatory cytokines such as IL-2,
IFN-γ and TGF-β are constitutively expressed. This cytokine production allows dendritic cells that
may otherwise inhibit proliferation to express immunosuppressive ligands such as CTLA-4, PD-1,
PDL-1 and PDL-2 during chronic inflammation [60,61]. Expression of anti-inflammatory cytokines
downregulates MHC Class II activation and diminishes the innate immune response by reducing T cell
activation in the absence of stress. On the other hand, the modulation of T cells during injury can alter
the abundant population of natural killer (NK) T cells that facilitate apoptosis and T regulatory cells
(Tregs) that maintain cellular homeostasis [62–65]. It is important to understand these unique features
of the liver immunoanatomy to be able to recognize how HCC can hijack them to avoid immune
surveillance and promote tumor growth.
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4.2. Tumor Microenvironment
The HCC tumor utilizes the relative state of immunotolerance afforded to the liver to evade
detection, creating what is known as a tumor microenvironment. This microenvironment is comprised
of similar immunologic elements as the liver in its healthy state but with differing local recruitment,
cellular crosstalk and immunoanatomy. A schematic of normal versus tumor microenvironment is
represented in Figure 2. The progressive transformation from healthy liver to tumor microenvironment
occurs by continued disturbances to the normal immunologic homeostasis of the liver, notably through
secretion of immunosuppressive cytokines, abnormal expression of antigens and changes in the local
immune cell crosstalk during states of inflammation [66,67]. Specifically, during periods of acute
stress, hepatocytes may alter their own transcriptional profile to release acute phase reactants into
the blood or activate apoptotic or necrotic pathways [68–71]. Regeneration of injured hepatocytes,
especially at rapid rates, predisposes the new cells to mutagenesis and tumorigenesis, resulting in new
tumor-specific antigens being presented. Activation of these various pathways are etiology-dependent
and thus, antigens and receptors are differentially activated or suppressed in response to different
etiologies [68–70,72].
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Figure 2. Normal versus hepatocellular carcinoma (HCC) microenvironment.
In addition, there are cancer-specific immune responses. For example, there is the recruitment
of tumor-infiltrating lymphocytes (TILs), which normally reside in the tumor cells’ immediate
environment or sometimes within the stroma of the tumor [73]. TILs are lymphocytes designed
to identify cancer-specific tumor markers. These cells directly or indirectly kill tumor cells by
secreting IFN-γ, macrophage activating factors (MAF) and TNF-α or simply by activating apoptotic
cascades in tumor cells [34]. These cells contribute to the heterogeneous array of individual tumor
microenvironments in HCC. Specific HCC TILs have been identified, however their specificity to
individual etiologies and prognostic and therapeutic values have yet to be proven [74,75].
These factors create a variety of unique tumor microenvironments which help explain the
heterogeneity of the HCC tumors. In fact, the microenvironments are likely different even amongst
HCC tumors resulting from the same etiology. For example, one study showed distinct and
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differing populations of immune response cells have been found in HBV versus HCV HCC tumor
microenvironments [73,76].
Besides the HCC immunomodulation, cancer cells, in general, play a large role in shaping
the microenvironment based on their metabolic requirements. Cancer cells require accelerated
cellular growth, progressive mutagenesis and altered cellular metabolomics, creating a distinct
microenvironment around them to support these requirements characterized by relative hypoxia,
acidosis and aerobic glycolysis (known as the Warburg effect) [77]. This creates competition for oxygen
and nutrients with neighboring healthy cells, resulting in a hostile and hypoxic environment which
leads to further inflammation, fibrosis, immunomodulation and tumor cell creation [78–81]. As the
tumor grows, its microenvironment incorporates more and more nearby non-malignant cells and leads
to tumor invasion and metastasis [81,82]. This is the mechanism of HCC progression.
The tumor microenvironment is vital for mutagenesis, tumorigenesis and neoplastic proliferation
in HCC. The distinct nature of the microenvironments could provide specific targets, in the form of
TILs, modified APCs, activated macrophages or other unidentified antigens for immunotherapeutic
regimens [83]. This would unlock what we believe to be the future of etiology- and patient-specific
treatments in the form of targeted immunotherapy. While the liver itself does contain some unique
features, more research is needed to define how this compares to liver microenvironments of other
solid tumors or how it may influence the success or failure of immunotherapy options. Some current
treatments have attempted to utilize this mechanism, however many of them come with their own set
of limitations.
5. Current Immunotherapy Options
5.1. Cancer Vaccine
Similar to the development of routine vaccines, vaccines can also be created to prime a patient to
target tumor cells. These vaccines can be targeted to specific nucleic acids or polypeptides so that when
they present in a patient, the cells will be targeted by the hosts’ immune response [84,85]. There are
multiple clinical trials studying the role of vaccines in HCC alone and in combination with various
therapies targeting peptides such as alpha-fetoprotein (AFP) (NCT 00005629), a marker normally found
in fetal plasma and tested from maternal serum during pregnancy but erroneously secreted by certain
HCC tumors with an unknown function [86]. Others include vaccines against VEGFR1 and VEGFR2
(NCT 01266707), transcription factor proteins which promote tumor angiogenesis and against HCC
specific stem cells (NCT 02089919). No trials to date have produced any results, so efficacy remains to
be seen. However, given the difficulties associated with vaccine creation in general combined with the
fact that HCC is both heterogeneous and mutable, we are likely very far from a universally effective
HCC vaccine.
5.2. Programmed Cell Death Protein 1 (PD-1) Inhibitors
Direct targeting of immunosuppressive receptor-ligand interactions offers a potential method
of slowing tumor progression. PD-1 is a T cell receptor which inhibits T cell activation promoting
tolerance which, in the tumor microenvironment, allows unchecked tumor proliferation and has
been found on TILs in the HCC tumor microenvironment [87]. Previous studies showed that PD-1
expression diminishes HBV viral clearance and induces T cell exhaustion in HCV ultimately allowing
for immune cell evasion [88–90]. PD-1 inhibitors are small proteins which block interactions between
PD-1 and its ligands, preventing the subsequent cell signaling cascade and checkpoint inhibition [87].
PD-1 inhibitors have previously been approved for certain cancers including melanoma and non-small
cell lung carcinoma [91]. In a meta-analysis, PD-1 inhibitors (nivolumab and pembrolizumab) showed
a pooled response rate of 17.3% (defined as halting of tumor progression, signs of tumor regression
or tumor resolution) and overall survival of 10.4 months in patients with advanced HCC [92,93].
These rates are similar to those seen with sorafenib treatment but patients in this meta-analysis had less
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harsh side effect profiles [92,93]. Interestingly, one study noted differing responses whether HBV or
HCV was the inciting disease, likely because HCV is an RNA virus and does not include any genomic
integration [94]. While offering a more favorable side effect profile, early findings suggest that PD-1
inhibitors still offer only meager improvements in prognosis.
5.3. Cytotoxic T Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors
CTLA-4 or CD152, is an immune system checkpoint receptor which downregulates immune
system response by limiting co-stimulation, activation and subsequent proliferation of T cells through
competition against the normal co-stimulatory signal and were first studied in mesothelioma [95].
Tremelimumab is a CTLA-4 inhibitor studied in HCC patients who progressed on sorafenib and showed
promising anti-tumor activity and an acceptable safety profile [96]. In a study of 20 patients given
tremelimumab, the partial response rate or regression of tumor defined by the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria, was 18% (3/17). The disease control rate, defined as the
percentage of patients who had stable disease, partial regression or complete resolution after an
intervention was applied, was 76% (13/17) [96]. In addition, tremelimumab was studied in combination
with liver-directed therapy (TACE and TARE) in BCLC stage B & C patients with a partial regression
rate of 26% (5/19) but a 12 month tumor progression-free survival of 33.1% [97]. While highlighting
the benefit of multi-modality treatment, CTLA-4 inhibitors require more extensive studies in a larger
subset of patients to truly classify the HCC response as a success. Even then, little can be done to
combat HCC tumors which are resistant or become resistant to this therapy.
6. Chimeric Antigen Receptor (CAR) T Cell Based Therapy
First identified as a means to study T cell activation, chimeric antigen receptors (CARs) fused to
T cells were used by a group of scientists, including Carl June from the University of Pennsylvania,
to successfully treat a 5 year old girl named Emily Whitehead with relapsing acute lymphoblastic
leukemia (ALL) in 2010 [98]. CAR T cell therapy research increased following their success and was
first approved by the FDA in 2017 for the treatment of ALL [98]. It has since been approved for
treatment in certain types of non-Hodgkin lymphoma including aggressive, relapsed or refractory,
diffuse large B cell lymphoma, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma,
transformed follicular lymphoma and mantle cell lymphoma [99]. This therapy involves isolating T
cells from patients or donors and transfecting them with viral vectors containing specific chimeric
antigen receptor sequences that recognize previously characterized tumor cell antigens [100,101].
The structure of the CAR consists of an extracellular antigen recognition domain derived from the
variable portion of an antibody, a transmembrane domain and an intracellular domain that leads
to signal transmission [102]. The extracellular domain provides the specificity as it can be designed
against a specific antigen, while the potency of the immune response can be dictated by aggregation of
the intracellular domains in the presence of high antigen concentrations. Once these CAR T cells are
generated, they are returned back to the patient as an infusion. A graphic scheme of the process of
harvesting, creating and treating patients with CAR T cells is shown in Figure 3. In addition, later
iterations of CAR T cells have been developed to include their own co-stimulation signal, increasing
their potency and ability to kill [102]. The promise of CAR T therapy lies in the ability to modulate
therapy to target various, specific and predetermined antigens. Indeed, CAR T therapy for HCC has
multiple proposed antigen targets, some of which are displayed in Figure 4. Their specifics as well as
limitations are illustrated in the section below.
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6.1. Targets of CAR T Therapy
6.1.1. AFP/MHC complex
AFP is secreted and sometimes utilized as a tumor marker for HCC. Previously believed to
be too non-specific and non-functional to target, all proteins are presented in class I MHCs and,
thus, the opportunity to program CAR T cells to recognize this complex was established [103,104].
The issue with AFP is that expression levels do not necessarily correlate with stage of the disease or
may not be present at all [105]. Furthermore, little is known or agreed upon about its actual mechanism
or regulation, meaning that while this complex could be targeted, it could essentially be a decoy or
byproduct that has no mechanistic or functional consequence or worse, cause off-target unintended
detrimental effects [106].
6.1.2. MUC1
Mucin-1 (MUC-1) is also known as polymorphic epithelial mucin and is a group of glycoproteins
with high molecular mass that is overexpressed in human cancer cells including HCC cells [107].
A Phase I clinical trial of MUC-1 CAR T cells is currently underway for patients who have MUC-1
expressing HCC tumors (NCT02587689) [108]. No results are available from this trial yet. The limitation
with MUC-1 as a target is that antigens are heterogeneously expressed within individual tumors and
thus, the programming of CAR Ts in its current state may only target certain HCC tumors [109].
6.1.3. EpCAM
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein involved in
cell signaling, migration, proliferation and differentiation. It has been identified as a marker for
stem/progenitor cells of the liver and is disproportionately upregulated in HCC [110]. For this reason,
EpCAM may be a potential therapeutic target [111]. Two medical centers are currently testing EpCAM
CAR T cells in the clinical setting, looking at their safety and efficacy profiles and as a treatment for
HCC (NCT 03013712 and NCT 02729493) [112]. No results are available yet. Limitations are not yet
known but the heterogeneity of HCC and its presenting antigens may prove resistant to this CAR
T target.
6.1.4. GPC-3
Glypican-3 (GPC3) is a member of heparan sulfate proteoglycans and is located on the cell
surface. GPC3 is known to be upregulated in HCC as well as other solid tumors [113]. This protein
contributes to carcinogenesis by acting as a co-receptor for a common oncologic cell proliferation
pathway [114–116]. It has been studied as a tumor associated antigen as it is found in 70–80% of HCC
cells but is not found on normal adult human cells, a feature that separates its utility from other markers
of HCC [117]. Recently, a study showed that GPC3-targeted CAR T cells could eliminate orthotopic
and xenograft hepatocellular carcinomas in vitro and in vivo [117–119]. GPC3-targeted CAR T cells
could prove a promising therapy but additional verification for safety is currently underway with no
results available yet (NCT02395250). Newer studies are looking to combine these CAR T cell infusions
with other modes of delivery, such as intra-tumoral injection, to garner a greater sustained immune
response but no results are available for this study yet either (NCT03130712).
6.2. Limitations of CAR T Therapy
In the treatment of advanced HCC cancer, CAR T seems to overcome many barriers that current
therapies cannot. However, CAR T cell therapy creates a new set of obstacles that must be addressed.
Concerns with this mode of therapy include a reported “on-target, off-tumor” destruction of normal
cells as well as an exaggerated cytokine response when CAR T cells are infused, both of which can be
extremely harmful to the patient [101,120]. In regards to healthcare cost, while autologous treatments
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do exist, efficient and economic production of CAR T therapy lies in an ‘off-the-shelf’ model in which
healthy donor T cells are used. Consequently, the donor’s T cells must be characterized prior to T cell
isolation and CAR T cell creation as not all recipients may be compatible, creating the opportunity for
more patient harm [121]. Current work is being done to further refine the antigen specificity through
structural changes as well as programming an inducible suicide switch in each CAR T cell to promote
regulation to prevent some of these issues [122,123].
Additionally, while targets may be accessed via infusions in hematologic malignancies or cancers of
circulating blood cells such ALL, solid tumors are static and surrounded by a tumor microenvironment.
As we have discussed, HCC tumor cells are particularly adept at altering and evading immune responses,
ultimately hindering CAR T immune cell trafficking and diminishing efficacy significantly [100,120].
Another issue involves the lack of consistent antigen presentation in solid tumors leading to ineffective
target definition even within one etiology [101].
There has been parallel work done in the field of immunotherapy on the use of autogenously-generated
anti-tumor lymphocytes in the treatment of advanced HCC. Preliminary studies using various HCC
targets have been performed in patients, with moderately improved responses. Some studies reported
increases in survival from 30 months to 44 months on average as well as increases in disease-free
survival over 1-year (RR = 1.23), 2-year (RR = 1.37) and 3-years (RR = 1.35) in patients who received
adjuvant autogenously-generated activated cytokine-induced killer T cells and natural killer cells after
either surgical resection, radiofrequency ablation or percutaneous ethanol injection [124]. In addition,
modest improvements in overall survival at 1-year (RR = 1.08), 2-years (RR = 1.14) and 3-years
(RR = 1.15) are reported in a meta-analysis of that same patient population [125]. While showing
the feasibility of immunotherapy for advanced HCC, these findings spotlight the need for additional
refinement in CAR T therapy as the next generation of treatment. The promise of this modality is there
is the potential for patient-specific programmable targeting, which can address the continued problem
of HCC heterogeneity.
7. Multimodal Therapy
Single-modality therapy options each have their own set of limitations leading to decreased
efficacy. Only 10–20% of treated HCC patients show a durable response to current treatment. However,
a multimodal approach has been explored in HCC treatment, with the most promising combinations
involving immunotherapy.
7.1. Systemic Therapies and Checkpoint Inhibitors
One strategy trialed was the combination of checkpoint inhibitors and systemic therapies, in the
hopes of augmenting the effect of systemic therapy. PD-1 inhibitors, as well as other checkpoint
inhibitors, have been trialed in combination with sorafenib and have shown increased anti-tumor effects
in in vivo models. Unfortunately, in humans, disease-free and overall survival were not statistically
increased and the combination requires more broad randomized control trials [126,127].
7.2. Locoregional Therapy
To overcome the aforementioned immune cell trafficking barriers of systemically infused CAR T
therapies, techniques developed for TARE are being used to deliver CAR T cell infusions [100]. Highly
selective catheterization of branches of the hepatic artery as well as injection directly into the tumor
itself ensure optimal localization [128]. This could potentially eliminate the immune cell trafficking
issue limiting CAR T therapy, as well as overcome the resistant HCC tumor microenvironment.
In addition, radiofrequency ablation and irradiation can be combined with either systemic
or directly infused CAR T cell to improve the efficacy of CAR T cells by generating a localized
immune response which leads to increased antigen presentation [129,130]. This approach has shown
improvement in the native antitumor response compared to single-modality radiation therapy and has
even been shown to “downstage” patients rendering them eligible for resection or transplant [131,132].
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7.3. Post-Transplant
Though most immunotherapy options are presented to patients that are not surgical candidates,
for the growing population of post-transplant patients there is a risk of developing recurrent HCC
which would require systemic treatments. Immunosuppression, a requirement after transplant,
has historically excluded the transplant population from clinical trials using immunotherapy due to
concerns for decreased efficacy and increased harm in this patient population using this modality.
PD-1 inhibitors were contraindicated in patients with previous solid organ transplantation as there
is a documented risk of organ rejection, quoted to be 37.5% in liver transplants, in a systematic
review [133]. However, more recently, there have been case reports suggesting a benefit in the use of
PD-1 inhibitors in this population [134,135]. Currently, there is one clinical trial assessing the safety and
efficacy of PD-1 inhibitors in patients with previous liver transplant that have recurrence of the disease
which is not amenable to other therapeutic options (NCT 03966209). As this population continues to
grow over the coming decades, information must be accumulated in which therapeutics are safe and
efficacious for patients unfortunate enough to be afflicted by recurrent disease.
8. Conclusions
Hepatocellular carcinoma is a significant cause of morbidity and mortality worldwide, with no
reliable method to detect the disease early in its progression. This is combined with the fact that
systemic treatments available offer modest, at best, improvements in overall survival and disease-free
survival in advanced or recurrent HCC, highlighting the need for novel therapeutic strategies to
treat advanced stage HCC patients. To date, the most promising modality to offer this solution
is immunotherapy.
While multi-modal treatment may offer augmented HCC response rates when tested properly,
this option likely will not address the heart of the issue—HCC is a heterogeneous disease of multiple
and often-times interwoven, etiologies. Its complex immunomodulation and tumor microenvironment
require even more specific and individual treatments, something most obtainable by immunotherapy.
The future of HCC treatment must strive for a patient-specific, tumor-specific treatment and do so in
a reproducible and cost-effective manner.
If we can correctly identify and exploit druggable targets utilizing immunotherapy on an individual
level, we can begin to slow disease progression, downstage patients to be eligible for surgical resection,
combine it with surgical resection for improved results or eliminate the need for surgical resection
altogether. In this regard, CAR T cell therapy, with its unlimited programmable potential, could be the
key to unlock the personalized HCC treatment needed to treat this heterogeneous disease.
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